Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

This study tests whether HRS-7535, an investigational weight-loss drug in the GLP-1/GIP receptor agonist class, can improve heart function and reduce symptoms in people who have heart failure with a preserved or mildly reduced pumping ability, and who are also obese. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with chronic heart failure for at least 1 month - Your heart failure is the type with preserved or mildly reduced ejection fraction - Your BMI is 28 or above - You have had stable diet and exercise habits for the past 3 months with no major weight changes - Your heart failure symptoms are classified as NYHA Class II-IV **You may NOT be eligible if...** - You have type 1 diabetes or require insulin treatment - You have serious kidney, liver, or pancreatic disease - You are pregnant or breastfeeding - You have had a recent heart attack or hospitalization for heart failure Talk to your doctor to see if this trial is right for you.